TIGIT and cervical cancer: Besides the widely researched target such as CTLA-4 and PD-1/PD-L1, some novel co-inhibitory immune checkpoints and their antibodies have also been explored in cervical cancer, such as TIGIT, LAG-3, and TIM-3.